Detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug Qnexa in 2,487 patients across 93 sites in the United States. Data published in the peer-reviewed journal provided an in-depth look at weight loss and improvements in the full spectrum of comorbidities studied as secondary endpoints, including cardiovascular, metabolic, and inflammatory risk factors.
"Obesity is a serious medical condition associated with increased mortality from cardiovascular diseases, diabetes, cancer, and other diseases, yet there is a lack of treatment options for the one-third of American adults who are obese," said Kishore Gadde, MD, director of obesity clinical trials at Duke University and lead investigator. "Half the patients in the study had at least three comorbidities including diabetes, representing a population with the greatest medical need for weight loss. We observed significant weight loss, improvements in comorbidities, and a reduction in the need for concomitant medications in patients treated with Qnexa."
Results showed that average weight loss for Qnexa patients who completed the CONQUER study on the drug was 28 pounds and 22 pounds with top-dose Qnexa and mid-dose Qnexa, respectively, compared to 4 pounds in the placebo group.
More patients completed 1 year of treatment in the Qnexa groups, mid dose (69%) and top dose (64%), respectively, as compared to 57% in the placebo group. Qnexa therapy was well tolerated, with no unexpected adverse events. The most common side effects were dry mouth, paresthesia (tingling), constipation, insomnia, dizziness, and dysgeusia (altered taste). Rates of serious adverse events were similar across treatment groups: 4% with placebo, 3% with mid-dose Qnexa, and 5% with top-dose Qnexa. Most adverse events were seen early in treatment, and there was a low dropout rate due to adverse events, 12% and 19% for mid and top dose, respectively, compared to 9% for placebo.
